About InvaGen
InvaGen is a Healthcare company based in Hauppauge (United States) founded in 2003, and was acquired by Cipla in September 2015. Generic pharmaceuticals are developed and marketed across therapeutic areas. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.
Company details
InvaGen was founded in 2003 and is based in Hauppauge, United States. Generic pharmaceuticals are developed and marketed by the company in therapeutic areas such as diabetes, cardiovascular, infectious, neurological, and inflammatory diseases. Operations focus on a broad range of generic products. The company was acquired by Cipla in September 2015, integrating it into a larger pharmaceutical network.
- Headquarters Hauppauge, United States
- Stage Acquired
- SectorsHealthcare
- Website invagen.com
- Acquired by Cipla (Sep 2015)
Investors in InvaGen
InvaGen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Cipla.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
APIs, generic drugs, and formulation services are manufactured. | 1935 | cipla.com | Mumbai, India |
Investor details for InvaGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of InvaGen
2 dated milestones of InvaGen across 12 years, from founding to its latest funding, stage changes and deals.
- Founded InvaGen is founded.
- Exit Acquired by Cipla.
Web traffic of InvaGen
Websites that share an audience with InvaGen (invagen.com).
Websites whose visitors overlap most with InvaGen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| noven.com | 27% | 7.2K | #3,107,578 | View details |
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as InvaGen (Traditional Health & Nutrition) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | USD 3.02 B | 8,300 | ||
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | USD 5.1 B | 13,500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Invagen
Complete news archive for InvaGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InvaGen
InvaGen was founded in 2003.
InvaGen is headquartered in Hauppauge, United States. It is registered at Hauppauge, New York, United States.
InvaGen was founded in 2003 and is based in Hauppauge, United States. Generic pharmaceuticals are developed and marketed by the company in therapeutic areas such as diabetes, cardiovascular, infectious, neurological, and inflammatory diseases. Operations focus on a broad range of generic products. The company was acquired by Cipla in September 2015, integrating it into a larger pharmaceutical network.
InvaGen has 1 investor. Key investors include Cipla.
Yes. InvaGen was acquired by Cipla in September 2015.